Tracking genomic cancer evolution for precision medicine: the lung TRACERx study.
Authors
Jamal-Hanjani, MHackshaw, A
Ngai, Y
Shaw, J
Dive, Caroline
Quezada, S
Middleton, G
de Bruin, E
Le Quesne, J
Shafi, S
Falzon, M
Horswell, S
Blackhall, Fiona H
Khan, I
Janes, S
Nicolson, M
Lawrence, D
Forster, M
Fennell, D
Lee, S
Lester, J
Kerr, K
Muller, S
Iles, N
Smith, S
Murugaesu, N
Mitter, R
Salm, M
Stuart, A
Matthews, N
Adams, H
Ahmad, T
Attanoos, R
Bennett, J
Birkbak, N
Booton, R
Brady, G
Buchan, K
Capitano, A
Chetty, M
Cobbold, M
Crosbie, P
Davies, H
Denison, A
Djearman, M
Goldman, J
Haswell, T
Joseph, L
Kornaszewska, M
Krebs, M
Langman, G
MacKenzie, M
Millar, J
Morgan, B
Naidu, B
Nonaka, Daisuke
Peggs, K
Pritchard, C
Remmen, H
Rowan, A
Shah, R
Smith, E
Summers, Yvonne J
Taylor, M
Veeriah, S
Waller, D
Wilcox, B
Wilcox, M
Woolhouse, I
McGranahan, N
Swanton, C
Affiliation
Translational Cancer Therapeutics Laboratory, University College London Cancer Institute, London, United Kingdom; Department of Medical Oncology, University College London Hospitals, London, United Kingdom.Issue Date
2014-07
Metadata
Show full item recordAbstract
The importance of intratumour genetic and functional heterogeneity is increasingly recognised as a driver of cancer progression and survival outcome. Understanding how tumour clonal heterogeneity impacts upon therapeutic outcome, however, is still an area of unmet clinical and scientific need. TRACERx (TRAcking non-small cell lung Cancer Evolution through therapy [Rx]), a prospective study of patients with primary non-small cell lung cancer (NSCLC), aims to define the evolutionary trajectories of lung cancer in both space and time through multiregion and longitudinal tumour sampling and genetic analysis. By following cancers from diagnosis to relapse, tracking the evolutionary trajectories of tumours in relation to therapeutic interventions, and determining the impact of clonal heterogeneity on clinical outcomes, TRACERx may help to identify novel therapeutic targets for NSCLC and may also serve as a model applicable to other cancer types.Citation
Tracking genomic cancer evolution for precision medicine: the lung TRACERx study. 2014, 12 (7):e1001906 PLoS Biol.Journal
PLoS BiologyDOI
10.1371/journal.pbio.1001906PubMed ID
25003521Type
ArticleLanguage
enISSN
1545-7885ae974a485f413a2113503eed53cd6c53
10.1371/journal.pbio.1001906
Scopus Count
Collections
Related articles
- Tracking the Evolution of Non-Small-Cell Lung Cancer.
- Authors: Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R, Rosenthal R, Salm M, Horswell S, Escudero M, Matthews N, Rowan A, Chambers T, Moore DA, Turajlic S, Xu H, Lee SM, Forster MD, Ahmad T, Hiley CT, Abbosh C, Falzon M, Borg E, Marafioti T, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Dentro S, Taniere P, O'Sullivan B, Lowe HL, Hartley JA, Iles N, Bell H, Ngai Y, Shaw JA, Herrero J, Szallasi Z, Schwarz RF, Stewart A, Quezada SA, Le Quesne J, Van Loo P, Dive C, Hackshaw A, Swanton C, TRACERx Consortium.
- Issue date: 2017 Jun 1
- Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.
- Authors: Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Marie Quinn A, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG, TRACERx consortium., PEACE consortium., Swanton C
- Issue date: 2017 Apr 26
- Chromosome Instability Drives Tumor Evolution.
- Issue date: 2017 Jun
- Multiregion sequencing reveals the intratumor heterogeneity of driver mutations in TP53-driven non-small cell lung cancer.
- Authors: Zhang LL, Kan M, Zhang MM, Yu SS, Xie HJ, Gu ZH, Wang HN, Zhao SX, Zhou GB, Song HD, Zheng CX
- Issue date: 2017 Jan 1
- Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.
- Authors: Li T, Kung HJ, Mack PC, Gandara DR
- Issue date: 2013 Mar 10